CRONOS GROUP INC. Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure
CRONOS GROUP INC. (CRON) reported Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure of $901.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure · last filed 2026-08-06
- CRONOS GROUP INC. concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2026-06-30 was $6.41M, a 167.53% increase year-over-year.
- CRONOS GROUP INC. concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2026-03-31 was $895.03M, a 1.11% increase year-over-year.
- CRONOS GROUP INC. concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2025-12-31 was $25.09M.
- CRONOS GROUP INC. concentration risk, credit risk, financial instrument, maximum exposure for the quarter ending 2025-09-30 was -$2.81M.
- CRONOS GROUP INC. concentration risk, credit risk, financial instrument, maximum exposure for fiscal 2024 was $904.10M, a 6.45% decline from fiscal 2023.
- CRONOS GROUP INC. concentration risk, credit risk, financial instrument, maximum exposure for fiscal 2023 was $966.44M, a 2.17% decline from fiscal 2022.
- CRONOS GROUP INC. concentration risk, credit risk, financial instrument, maximum exposure for fiscal 2022 was $987.84M, a 11.70% decline from fiscal 2021.
- CRONOS GROUP INC. concentration risk, credit risk, financial instrument, maximum exposure for fiscal 2021 was $1.12B, a 20.29% decline from fiscal 2020.
| Period end | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 3 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 6 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 6 month as first filed | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 9 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 12 month | Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $901.44M 10-Q · filed 2026-08-06 | $926.53M derived: sum of 3 quarters · filed 2026-08-06 | $923.72M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $895.03M 10-Q · filed 2026-05-11 | $920.12M derived: sum of 2 quarters · filed 2026-08-06 | $917.31M derived: sum of 3 quarters · filed 2026-08-06 | $919.71M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $25.09M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | $22.28M derived: sum of 2 quarters · filed 2026-08-06 | $24.68M derived: sum of 3 quarters · filed 2026-08-06 | $909.84M 10-Q · filed 2026-08-06 | ||
| 2025-09-30 | -$2.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$412.00K derived: sum of 2 quarters · filed 2025-11-06 | $884.75M 10-Q · filed 2025-11-06 | $877.14M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2025-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $887.56M 10-Q · filed 2025-08-07 | $879.95M derived: sum of 3 quarters · filed 2026-02-26 | $836.84M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2025-03-31 | $885.16M 10-Q · filed 2025-05-08 | $877.55M derived: sum of 2 quarters · filed 2026-02-26 | $834.45M derived: sum of 3 quarters · filed 2026-02-26 | $836.82M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-12-31 | -$7.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$50.72M derived: sum of 2 quarters · filed 2026-02-26 | -$48.34M derived: sum of 3 quarters · filed 2026-02-26 | $904.10M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | -$43.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$40.73M derived: sum of 2 quarters · filed 2024-11-12 | $911.71M 10-Q · filed 2024-11-12 | $932.98M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2024-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $954.82M 10-Q · filed 2024-08-08 | $976.08M derived: sum of 3 quarters · filed 2025-02-27 | $977.38M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2024-03-31 | $952.45M 10-Q · filed 2024-05-09 | $973.71M derived: sum of 2 quarters · filed 2025-02-27 | $975.00M derived: sum of 3 quarters · filed 2025-02-27 | $982.93M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-12-31 | $21.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $22.56M derived: sum of 2 quarters · filed 2025-02-27 | $30.49M derived: sum of 3 quarters · filed 2025-02-27 | $966.44M 10-K · filed 2025-02-27 | ||
| 2023-09-30 | $1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $9.22M derived: sum of 2 quarters · filed 2023-11-08 | $945.18M 10-Q · filed 2023-11-08 | $940.63M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2023-06-30 | $7.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $943.88M 10-Q · filed 2023-08-08 | $939.34M derived: sum of 3 quarters · filed 2024-02-29 | $879.23M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2023-03-31 | $935.96M 10-Q · filed 2023-05-09 | $931.41M derived: sum of 2 quarters · filed 2024-02-29 | $871.30M derived: sum of 3 quarters · filed 2024-02-29 | $825.38M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-12-31 | -$4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$64.66M derived: sum of 2 quarters · filed 2024-02-29 | -$110.58M derived: sum of 3 quarters · filed 2024-02-29 | $987.84M 10-K · filed 2024-02-29 | $987.44M 10-K · filed 2023-02-28 | |
| 2022-09-30 | -$60.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$106.03M derived: sum of 2 quarters · filed 2022-11-07 | $992.38M 10-Q · filed 2022-11-07 | $966.93M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2022-06-30 | -$45.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.05B 10-Q · filed 2022-08-09 | $1.03B derived: sum of 3 quarters · filed 2023-02-28 | $1.05B derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2022-03-31 | $1.10B 10-Q · filed 2022-05-10 | $1.07B derived: sum of 2 quarters · filed 2023-02-28 | $1.10B derived: sum of 3 quarters · filed 2023-02-28 | $868.77M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-12-31 | -$25.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | -$229.64M derived: sum of 3 quarters · filed 2023-02-28 | $1.12B 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $25.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-18 | -$204.18M derived: sum of 2 quarters · filed 2022-05-10 | $1.14B 10-Q · filed 2022-02-18 | $1.15B derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2021-06-30 | -$229.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-10 | $1.12B 10-Q · filed 2022-05-10 | $1.21B 10-Q · filed 2021-08-06 | $1.12B derived: sum of 3 quarters · filed 2022-05-10 | $1.10B derived: sum of 4 quarters · filed 2022-05-10 | |
| 2021-03-31 | $1.35B 10-Q · filed 2021-05-07 | $1.35B derived: sum of 2 quarters · filed 2022-03-01 | $1.33B derived: sum of 3 quarters · filed 2022-03-01 | $1.33B derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$21.30M derived: sum of 2 quarters · filed 2022-03-01 | -$17.32M derived: sum of 3 quarters · filed 2022-03-01 | $1.40B 10-K · filed 2022-03-01 | ||
| 2020-09-30 | -$23.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$19.20M derived: sum of 2 quarters · filed 2020-11-05 | $1.40B 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.42B 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $1.42B 10-Q · filed 2020-05-08 | |||||
| 2019-12-31 | $1.59B 10-K · filed 2021-02-26 | |||||
| 2019-03-31 | $1.59B 10-Q · filed 2020-05-08 | |||||
| 2018-12-31 | $34.41M 10-K/A · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |